Nanobiotix (ENXTPA:NANO) Could Be 44% Undervalued After Weak Half Year Results

Nanobiotix (ENXTPA:NANO) just released its half-year 2026 results, reporting a notable decline in sales and revenue along with a significantly larger net loss, which has brought increased attention to its cash burn.

The earnings release appears to have reset expectations for Nanobiotix in the short term, with a 30 day share price return of down 19.58% and a 90 day share price return of down 6.30%. However, the year to date share price return of 53.47% and a one year total shareholder return of 121.58% still point to strong longer term momentum.

Scan how other cancer and biotech plays are reacting to similar earnings shocks and clinical updates by reviewing our curated 618 high quality undiscovered gems for fresh ideas beyond Nanobiotix.

Nanobiotix now sits at the crossroads of a harsh earnings reset and upbeat trial headlines. How much of the recent share price swing reflects sentiment rather than a change in fundamental value?

Most Popular Narrative: 44% Undervalued

Nanobiotix is priced at €29.16 against a widely followed fair value of €52.20. The central story leans heavily on future execution supported by a 6.83% discount rate and ambitious growth and margin assumptions.

The collaboration with Johnson & Johnson on NBTXR3, including a large Phase III in head and neck cancer and the CONVERGE Phase II in lung cancer, concentrates development on indications that management describes as sizable markets. This collaboration could influence future product revenue and milestone inflows if these programs progress.

Refocusing internal resources toward the Curadigm platform and other new drug classes, supported by four recent patent applications and ongoing IND enabling work, can shift the cost base toward programs the company fully owns. This may have an impact on long term gross margins and operating leverage.

See why 2 investors see Nanobiotix as 44% undervalued.

Result: Fair Value of €52.20 (UNDERVALUED)

Still, the Nanobiotix story can break if key NBTXR3 trials disappoint or if Curadigm partnerships fail to convert from MTAs into paying agreements.

Find out about the key risks to this Nanobiotix narrative.

Next Steps

Mixed messages in the Nanobiotix story so far, with both pressure points and bright spots in view, mean your own judgment matters more than ever right now. Take a moment to review the underlying data, weigh the 1 or more risks against the 1 or more rewards, and then drill into the 2 key rewards and 2 important warning signs.

Looking for more Nanobiotix investment ideas?

If you only stop at Nanobiotix, you risk missing other opportunities that match your goals, risk profile, and preferred balance between quality and price.

• Target steadier compounding by focusing on companies with robust finances and consistent metrics through our list of solid balance sheet and fundamentals (201 results).
• Hunt for mispriced quality by scanning companies that our models flag as attractively valued using the 185 high quality undervalued stocks.
• Lock in potential income streams by reviewing businesses with higher yields and strong payout support in the 159 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com